SARS-CoV-2/COVID-19 has already caused over 50,000 deaths, infected a million people worldwide, triggered massive economic disruption and changed how the entire world moves and interacts. The race to find a vaccine to prevent this disease is on.
To meet the dire need for vaccines, treatments and diagnostics, funders and the scientific community have stepped up rapidly. As of the 20th March there were 42 candidate vaccines being developed, with two already in Phase 1 clinical trials.
A Coronavirus human infection study could potentially allow for those vaccines currently being developed to be available to the public faster than traditional vaccine development, and some studies are already in development by researchers such as hVIVO.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).
